Sequencing among our ADCs is definitely getting tricky and not just in the HER2 space. So right now our standard first line treatment is taxane with trastuzumab and pertuzumab. Now, patients may not get this if they get that in the neoadjuvant setting and then relapse very quickly within 12 months of already receiving it. But for most patients, that’s typically the way it goes. And then we’re probably thinking about trastuzumab deruxtecan in the second line...
Sequencing among our ADCs is definitely getting tricky and not just in the HER2 space. So right now our standard first line treatment is taxane with trastuzumab and pertuzumab. Now, patients may not get this if they get that in the neoadjuvant setting and then relapse very quickly within 12 months of already receiving it. But for most patients, that’s typically the way it goes. And then we’re probably thinking about trastuzumab deruxtecan in the second line. And then third line and beyond is a little bit more up near. I personally am using a lot of capecitabine with trastuzumab and tucatanib in the third line. It improved overall survival. It’s very good drug for brain mets. And we’re hoping, although we don’t know this yet, that it might even be preventative for brain mets. And then we certainly can cycle back and think about something like T-DM1 as well for our patients.